garenoxacin has been researched along with Bacterial Infections, Gram-Negative in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blondeau, JM; Hansen, GT | 1 |
| Citron, DM; Fernandez, H; Goldstein, EJ; Merriam, CV; Tyrrell, KL; Warren, YA | 1 |
| Gordon, KA; Jones, RN; Pfaller, MA | 1 |
3 other study(ies) available for garenoxacin and Bacterial Infections, Gram-Negative
| Article | Year |
|---|---|
Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Urinary Tract Infections | 2005 |
In vitro activities of a new des-fluoroquinolone, BMS 284756, and seven other antimicrobial agents against 151 isolates of Eikenella corrodens.
Topics: Anti-Infective Agents; Drug Resistance, Microbial; Eikenella corrodens; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Indoles; Microbial Sensitivity Tests; Quinolones | 2002 |
BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000).
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Fluoroquinolones; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Indoles; Microbial Sensitivity Tests; Population Surveillance; Quinolones | 2002 |